Results 41 to 50 of about 2,792 (97)

Narsoplimab Results in Excellent Survival in Adults and Children With Hematopoietic Cell Transplant Associated Thrombotic Microangiopathy (TA‐TMA)

American Journal of Hematology, Volume 100, Issue 11, Page 2040-2051, November 2025.
ABSTRACT Inappropriate complement activation is a key driver of hematopoietic cell transplant‐associated thrombotic microangiopathy (TA‐TMA). Treatment with narsoplimab, an inhibitor of MASP‐2, the effector enzyme of the lectin pathway, resulted in a response rate of 61% in a Phase 2 clinical trial in adults with TA‐TMA.
Michelle L. Schoettler, Sunil Kumar Pusarla, Narinder Nangia, Miguel‐Angel Perales, Rafael F. Duarte, Andreas Grauer, Alessandro Rambaldi   +6 more
wiley   +1 more source

Gastric Signet Ring Cell Carcinoma: Tumor Microenvironment Reprogramming and Novel Therapeutic Targets With Emphasis on GRIN2D

Clinical and Translational Science, Volume 18, Issue 11, November 2025.
ABSTRACT Gastric Signet Ring Cell Carcinoma (GSRCC) is an increasingly recognized subtype of gastric cancer, particularly prevalent in South Asian populations and regions within India. This carcinoma is distinguished by its abundant cytoplasmic mucinous cells and aggressive clinical behavior, often affecting younger individuals and leading to a poor ...
Dipali Raju, Swathi Prabhu, Anjal Maria, Shriya Narendra Shet Shirodkar, Rama Rao Damerla, Sanjiban Chakrabarty, Preethi S. Shetty, Mahadev Rao, Naveena A. N. Kumar   +8 more
wiley   +1 more source

Revisiting Glomerulopathy in Clusterin Knockout Mice: A Mouse Model of Human Immunotactoid Glomerulopathy

Nephrology, Volume 30, Issue 11, November 2025.
Key findings: This study confirmed that the glomerulopathy in CLU‐KO B6 mice was similar to the pathological features of ITG and may be therefore considered as an experimental model of ITG. Further, CLU may negatively regulate the fibrillogenesis of ITG.
Xinglan Li, Xingwei Cai, Qiunong Guan, Junya Tan, Xudan Yang, Changhong Wu, Caigan Du   +6 more
wiley   +1 more source

Complement C3 recognition by C3 convertases. [PDF]

Sci Adv
Jia C, Yang X, Zhao MH, Tan Y, Xiao J.
europepmc   +1 more source

Primary membranoproliferative glomerulonephritis: natural history, pathogenesis, and treatment. [PDF]

Front Nephrol
Filippone EJ, Farber JL.
europepmc   +1 more source

Complement-mediated HUS revisited: evolving insights into pathophysiology, diagnosis, and treatment. [PDF]

Front Immunol
Alyamany R, Moyer AM, Willrich MAV, Sridharan M.   +3 more
europepmc   +1 more source

Advances in complement research: from pathophysiology to precision medicine. [PDF]

Physiology (Bethesda)
Thurman JM, Thurman JM.
europepmc   +1 more source

Structural insights into C3 convertase activity of the classical pathway of complement. [PDF]

Nat Commun
De la O Becerra KI, Brondijk THC, Serna Martin I, Gros P.   +3 more
europepmc   +1 more source

Paroxysmal Nocturnal Hemoglobinuria: Unraveling Its Molecular Pathogenesis and Advancing Targeted Therapeutic Strategies. [PDF]

Diseases
Apostolidou E, Georgoulis V, Leonardos D, Kapsali E, Hatzimichael E.   +4 more
europepmc   +1 more source

A cut above: atypical proteolysis endows complement C3 with non-canonical immune activities. [PDF]

EMBO J
West EE, Kemper C.
europepmc   +1 more source